Nuwellis, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

About this update from Nuwellis, Inc.

[{"type":"image","alt":"Nuwellis, Inc.","displaySize":"","headline":null,"caption":"Nuwellis, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":72,"url":"https://media.zenfs.com/en/globenewswire.com/d2460037586c5d451999b7d63383d34b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/epm_zxode7LAVlWVBg62FQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d2460037586c5d451999b7d63383d34b","width":300,"height":72}},"lazy":false},{"type":"text","content":"MINNEAPOLIS, May 13, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical device company dedicated to transforming care for fluid overload patients, today announced financial results for the first quarter ended March 31, 2025, and provided a business update.","length":288,"tagName":"p"},{"type":"text","content":"First Quarter 2025 and Recent Business Highlights","length":49,"tagName":"p"},{"type":"text","content":"Nuwellis continued to advance its strategic priorities during the first quarter, delivering growth in customer categories and strengthening the foundation for broader adoption of Aquadex therapy. Higher CMS reimbursement, strong pediatric performance, and disciplined expense management position the company to capitalize on both inpatient growth and emerging outpatient opportunities in 2025.","length":393,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue of $1.9 million, a 3% increase over the prior-year quarter.","length":67,"tagName":"p"}]},{"val":[{"type":"text","content":"4% growth in consumables utilization year-over-year.","length":52,"tagName":"p"}]},{"val":[{"type":"text","content":"Pediatric revenue grew 38% year-over-year.","length":42,"tagName":"p"}]},{"val":[{"type":"text","content":"Operating expense reduction of $1.8 million, or 31%, compared to the prior-year quarter.","length":88,"tagName":"p"}]},{"val":[{"type":"text","content":"Effective January 1, 2025, CMS reassigned Aquadex to a higher outpatient reimbursement level, increasing the facility fee nearly four-fold to $1,639 per day.","length":157,"tagName":"p"}]},{"val":[{"type":"text","content":"Expanded outpatient opportunity pipeline, driven by favorable reimbursement and supportive clinical data.","length":105,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":511,"olTy...

More updates from Nuwellis, Inc.